Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Circulerend tumor-DNA toont maanden eerder dan scan of kankertherapie effectief is
nov 2023 | Dermato-oncologie, Uro-oncologie